This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child...ren, and HIV co-infection are all fully addressed.
more
This diagnostic and treatment manual is designed for use by medical professionals involved in curative care at the dispensary and hospital levels. We have tried to respond in the simplest and most practical way possible to the questions and problems faced by field medical staff, using the accumulate...d field experience of Médecins Sans Frontières, the recommendations of reference organizations such as the World Health Organization (WHO) and specialized works in each field.
Available in English, French, Spanish and Arabic
more
Ce guide clinique et thérapeutique s’adresse aux professionnels de santé impliqués dans les soins curatifs au niveau des dispensaires et des hôpitaux. Nous avons essayé de répondre le plus simplement possible aux questions et problèmes auxquels est confronté le personnel de santé par des ...solutions pratiques, conciliant l’expérience acquise sur le terrain par Médecins Sans Frontières, les recommandations des organismes de référence tels que l’Organisation Mondiale de la Santé (OMS) et celles des ouvrages spécialisés en la matière.
more
Guidance for health workers
Weekly Epidemiological Record (WER), 17 September 2021, Vol. 96, No. 37 (pp. 445-460)
Guía práctica de utilización destinado a médicos, farmacéuticos, enfermeros y auxiliares sanitario.
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)....
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and formulation on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
Esta guía va dirigida a los profesionales de la salud que proporcionan asistencia curativa en dispensarios y hospitales. Hemos intentado responder a las preguntas y problemas con los que se enfrenta el personal sanitario, procurando dar soluciones prácticas y aunando la experiencia adquirida por M...édicos Sin Fronteras en el terreno, las recomendaciones de organismos de referencia como la Organización Mundial de la Salud y aquellas obras especializadas en la materia.
more
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...rmulations on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
Otros trastornos
Capítulo H.5.1
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Iván Olle Llopis
This report outlines and analyses the implementation of the Bridge Builder Model. This is a two-way, capacity-sharing model aimed at bringing together local faith actors (LFAs) and international humanitarian actors to increase understanding, trust, coordination and collaboration.
Mettre fin au choléra- Feuille de route mondiale pour 2030 rend opérationnelle la nouvelle stratégie mondiale de lutte contre le choléra au niveau des pays et fournit une voie concrète vers un monde où le choléra ne représente plus une menace pour la santé publique. En mettant en œuvre la ...stratégie d’ici à 2030, les partenaires du Groupe spécial mondial de lutte contre le choléra (GTFCC) aideront les pays à réduire de 90 % les décès dus au choléra. Avec l’engagement des pays touchés par le choléra, des partenaires techniques et des donateurs, pas moins de 20 pays pourraient éliminer la transmission de la maladie d’ici 2030.
more
The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
...
The 2022 edition of the report is as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2022, 202 countries and territories with more than 99% of the world’s population and TB cases reported data
more
Addressing comorbidities and risk factors for TB is a crucial component of Pillar one of the End TB Strategy, which focuses on integrated patient-centred care and prevention, including action on TB and comorbidities. The Framework for collaborative action on TB and comorbidities aims to support coun...tries in the evidence-informed introduction and scale-up of holistic people-centred services for TB, comorbidities and health-related risk factors, with the goal of comprehensively addressing TB and other co-existing health conditions. It should be used in conjunction with relevant WHO guidelines. The Framework is intended for use by people working in ministries of health, other relevant line-ministries, policymakers, international technical and funding organizations, researchers, nongovernmental and civil society organizations, as well as primary care workers, specialist health practitioners, and community health workers who support the response to TB and comorbidities in both the public and private sectors.
more
On 15–16 December 2020, WHO and the Medicines for Malaria Venture co-convened a technical consultation to consider the preferred product characteristics (PPCs) for drugs used in malaria chemoprevention. The main goal of the technical consultation was to agree on the most important PPCs for drugs t...o protect populations from malaria (chemoprevention), while considering relevant measures of efficacy and the safety data needed to support WHO policy recommendations.
more
This report presents key findings from a study carried out on ‘Assessing the effectiveness of targeting mechanisms under PMJAY’. It provides a detailed analysis of potential inclusion and exclusion errors in two select states in India (Haryana and Uttarakhand) to inform National Health Authority...’s (NHA) policy
and approach around beneficiary targeting.
more
Government of Nepal has an obligation to ensure availability of affordable and high quality basic health care services to its population
Guia de treinamento para profissionais de saúde da linha de frente
Versão oficial em português da obra original em Inglês
Recognizing neglected tropical diseases through changes on the skin: a training guide for front-line health workers
Many countries have made significant progress in the implementation of World Health Organization recommended preventive chemotherapy strategy, to eliminate lymphatic filariasis (LF). However, pertinent challenges such as the existence of areas of residual infections in disease endemic districts pose... potential threats to the achievements made. Thus, this study was undertaken to assess the importance of these areas in implementation units (districts) where microfilaria (MF) positive individuals could not be found during the mid-term assessment after three rounds of mass drug administration.
more
Analysis of microfilaria prevalence data from 430 communities